NCT03647670
- Conditions
- Phase 1
- Locations
-
- Pfizer Clinical Research Unit Brussels, Belgium
Clinical trial condition
Phase 1
Explore clinical trials studying Phase 1. Study availability and eligibility vary by location and protocol.
19 public trials
3 recruiting studies
Phase 1 trial results
NCT03883620
- Conditions
- Arbovirus Infections, Dengue, Flaviviridae Infections, +8 more
- Locations
-
- CMAX Clinical Research Pty Ltd Adelaide, South Australia, Australia
NCT01091532
- Conditions
- Multiple Dose, Pharmacokinetic, Phase 1, +2 more
- Locations
-
- Pfizer Investigational Site Brussels, Belgium
NCT03273192
- Conditions
- Bioequivalence, Phase 1
- Locations
-
- Orchidpharmed PK/PD site Tehran, Iran
NCT03273088
- Conditions
- Bioequivalence, Phase 1
- Locations
-
- Orchidpharmed PK/PD site Tehrān, Tehran Province, Iran
Completed
EC905 Pharmacokinetic Profile Study
NCT02634489
- Conditions
- Benign Prostatic Hyperplasia, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +20 more
- Locations
-
- Site NL1 Zuidlaren, Drenthe, Netherlands
- Conditions
- Bioavailability, Healthy Subjects, Phase 1
- Locations
-
- Parexel Berlin, Germany
NCT01415102
- Conditions
- Pharmacokinetics, Phase 1, Safety, +2 more
- Locations
-
- Pfizer Investigational Site Brussels, Belgium
Active, Not Recruiting
A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants
NCT07413367
- Conditions
- Open Label, Pharmakokinetic, Phase 1
- Locations
-
- Syneos Health Clinique, Inc. Québec, Quebec, Canada